Novartis, Genentech Get FDA OK of Self-Administered Xolair
13 April 2021 - 4:12AM
Dow Jones News
By Colin Kellaher
Roche Holding AG's Genentech unit and Novartis AG on Monday said
U.S. users of their blockbuster asthma treatment Xolair can now
administer the drug themselves.
The companies said the U.S. Food and Drug Administration
approved Xolair prefilled syringes for self-injection across all
approved U.S. indications.
Xolair, which was first approved in the U.S. in 2003 to treat
allergic asthma and is now also approved for chronic idiopathic
urticaria and nasal polyps, previously required administration by a
healthcare professional.
Novartis and Genentech, which work together to develop and
co-promote Xolair in the U.S., said self-administration of the drug
from home has become particularly important for patients who are
considered at high risk amid the Covid-19 pandemic.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 12, 2021 13:57 ET (17:57 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2024 to May 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From May 2023 to May 2024